Keyphrases
Neurofibromatosis Type I
100%
Phase II Trial
100%
Cabozantinib
100%
Plexiform Neurofibroma
100%
Adverse Events
66%
Neurofibromatosis Type 1 (NF-1)
50%
Partial Response
50%
Disease Progression
16%
Clinical Trials
16%
Magnetic Resonance Imaging
16%
Tyrosine Kinase
16%
Dose Reduction
16%
Pharmacokinetics
16%
Neoplasms
16%
Tumor Volume
16%
Quality of Life
16%
Cell Lineage
16%
Safety Efficacy
16%
Quality of Life Assessment
16%
Differential Modulation
16%
Safety Activity
16%
Sarcoma
16%
Gastrointestinal Toxicity
16%
Pain Interference
16%
Patient-reported Outcomes
16%
Cre Mice
16%
Neurofibromatosis
16%
Biologic Activity
16%
Tumor Volume Reduction
16%
Daily Life
16%
Trial Participants
16%
Tumor Pain
16%
Lesion Volume
16%
Pain Intensity
16%
Global Quality of Life
16%
Target Lesion
16%
Hypothyroidism
16%
Pain Improvement
16%
Palmar-plantar Erythrodysesthesia
16%
Therapy Discontinuation
16%
Circulating Endothelial Cells
16%
Medicine and Dentistry
Cabozantinib
100%
Neurofibromatosis
100%
Plexiform Neurofibroma
100%
Neoplasm
66%
Adverse Event
66%
Neurofibromatosis Type I
50%
Quality of Life
33%
Cytokine
16%
Clinical Trial
16%
Magnetic Resonance Imaging
16%
Protein Tyrosine Kinase
16%
Disease Exacerbation
16%
Patient-Reported Outcome
16%
Drive
16%
Kinase
16%
Gastrointestinal Toxicity
16%
Pharmacokinetics
16%
Cell Lineage
16%
Hand Foot Syndrome
16%
Drug Dose Reduction
16%
Hypothyroidism
16%
Target Lesion
16%
Circulating Endothelial Cell
16%
Connective Tissue Cancer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cabozantinib
100%
Neurofibroma
100%
Neurofibromatosis
100%
Neoplasm
66%
Adverse Event
66%
Neurofibromatosis Type 1
50%
Clinical Trial
16%
Cytokine
16%
Protein Tyrosine Kinase
16%
Disease Exacerbation
16%
Hypothyroidism
16%
Gastrointestinal Toxicity
16%
Hand Foot Syndrome
16%
Connective Tissue Cancer
16%
Pharmacokinetics
16%